Observational Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Mar 28, 2021; 27(12): 1226-1239
Published online Mar 28, 2021. doi: 10.3748/wjg.v27.i12.1226
Table 3 Demographic, clinical and treatment characteristics by states in Brazil
Characteristics
São Paulo
Rio de Janeiro
Minas Gerais
Santa Catarina
Paraná
Bahia
Distrito Federal
Rio Grande do Sul
Espírito Santo
Ceará
Pernambuco
Maranhão
Goiás
n = 1057 (%)
n = 336 (%)
n = 329 (%)
n = 278 (%)
n = 277 (%)
n = 217 (%)
n = 190 (%)
n = 183 (%)
n = 144 (%)
n = 107 (%)
n = 74 (%)
n = 57 (%)
n = 49 (%)
Clinical risk factors
Age ≥ 70 yr7 (0.7)2 (0.6)2 (0.6)7 (2.5)9 (3.2)1 (0.5)2 (1.1)-8 (5.6)5 (4.7)2 (2.7)--
Hypertension133 (12.6)43 (12.8)34 (10.3)27 (9.7)31 (11.2)29 (13.4)19 (10.0)11 (6.0)13 (9.0)14 (13.1)6 (8.1)2 (3.5)4 (8.2)
Diabetes33 (3.1)14 (4.2)7 (2.1)8 (2.9)13 (4.7)9 (4.1)9 (4.7)-8 (5.6)6 (5.6)2 (2.7)-3 (6.1)
Cardiovascular diseases23 (2.2)10 (3.0)4 (1.2)10 (3.6)12 (4.3)9 (4.1)9 (4.7)3 (1.6)8 (5.6)6 (5.6)2 (2.7)3 (5.3)1 (2.0)
Liver diseases52 (4.9)15 (4.5)12 (3.6)17 (6.1)11 (4.0)8 (3.7)10 (5.3)11 (6.0)5 (3.5)1 (0.9)3 (4.1)2 (3.5)2 (4.1)
Abdominal surgery for IBD (< 30 d)38 (3.6)12 (3.6)7 (2.1)11 (4.0)16 (5.8)5 (2.3)8 (4.2)1 (0.5)16 (11.1)5 (4.7)4 (5.4)1 (1.8)2 (4.1)
Overall IBD medications
No medication112 (10.6)40 (11.9)26 (7.9)22 (7.9)28 (10.1)16 (7.4)16 (8.4)15 (8.2)15 (10.4)6 (5.6)5 (6.8)7 (12.3)1 (2.0)
Oral steroids137 (13.0)50 (14.9)52 (15.8)32 (11.5)30 (10.8)34 (15.7)27 (14.2)23 (12.6)10 (6.9)16 (15.0)11 (14.9)6 (10.5)7 (14.3)
5-ASA357 (33.8)90 (26.8)124 (37.7)110 (39.6)90 (32.5)88 (40.6)68 (35.8)73 (39.9)20 (13.9)21 (19.6)37 (50.0)18 (31.6)19 (38.8)
AZA/6-MP/MTX308 (29.1)101 (30.1)130 (39.5)93 (33.5)95 (34.3)71 (32.7)51 (26.8)68 (37.2)62 (43.1)52 (48.6)27 (36.5)17 (29.8)21 (42.9)
Biologics575 (54.4)164 (48.8)156 (47.4)145 (52.2)153 (55.2)95 (43.8)93 (48.9)87 (47.5)92 (63.9)64 (59.8)28 (37.8)29 (50.9)29 (59.2)
Therapeutic regimen
Oral steroid monotherapy117 (1.6)14 (4.2)8 (2.4)5 (1.8)2 (0.7)8 (3.7)12 (6.3)4 (2.2)1 (0.7)1 (0.9)3 (4.1)--
5-ASA monotherapy1212 (20.1)57 (17.0)67 (20.4)67 (24.1)49 (17.7)68 (31.3)45 (23.7)46 (25.1)11 (7.6)12 (11.2)23 (31.1)12 (21.1)14 (28.6)
5-ASA + oral steroids239 (18.4)4 (7.0)9 (13.4)12 (17.9)5 (10.2)11 (16.2)5 (11.1)6 (13.0)1 (9.1)1 (8.3)1 (4.3)2 (16.7)6 (42.9)
AZA/6-MP/MTX monotherapy1141 (13.3)61 (18.2)72 (21.9)39 (14.0)45 (16.2)30 (13.8)24 (12.6)31 (16.9)25 (17.4)24 (22.4)15 (20.3)9 (15.8)5 (10.2)
AZA/6-MP/MTX + oral steroids228 (19.9)12 (19.7)11 (15.3)2 (5.1)10 (22.2)6 (20.0)3 (12.5)2 (6.5)2 (8.0)6 (25.0)2 (13.3)2 (22.2)-
Biologic monotherapy1408 (38.6)124 (36.9)98 (29.8)91 (32.7)103 (37.2)54 (24.9)66 (34.7)50 (27.3)55 (38.2)36 (33.6)16 (21.6)21 (36.8)13 (26.5)
Biologic + oral steroids221 (5.1)17 (13.7)18 (18.4)6 (6.6)9 (8.7)2 (3.7)5 (7.6)5 (10.0)4 (7.3)2 (5.6)3 (18.8)1 (4.8)1 (7.7)
Combo therapy3167 (15.8)40 (11.9)58 (17.6)54 (19.4)50 (18.1)41 (18.9)27 (14.2)37 (20.2)37 (25.7)28 (26.2)12 (16.2)8 (14.0)16 (32.7)
Combo therapy3 + oral steroids232 (19.2)3 (7.5)6 (10.3)7 (13.0)4 (8.0)7 (17.1)2 (7.4)6 (16.2)2 (5.4)6 (21.4)2 (16.7)1 (12.5)-
Risk classification
Low221 (21.0)71 (21.1)67 (20.4)65 (23.4)53 (19.1)51 (23.5)50 (26.3)46 (25.1)15 (10.4)16 (15.0)20 (27.0)11 (19.3)11 (22.4)
Medium579 (54.8)184 (54.8)193 (58.7)139 (50.0)156 (56.3)118 (54.4)91 (47.9)108 (59.0)86 (59.7)62 (57.9)40 (54.1)40 (70.2)24 (49.0)
High256 (24.8)81 (24.1)69 (21.0)74 (26.6)68 (24.5)48 (22.1)49 (25.8)29 (15.8)43 (29.9)29 (27.1)14 (18.9)6 (10.5)14 (28.6)
1Monotherapy indicates no concomitant biologics or aminosalicylates/6-mercaptopurine/methotrexate.
2These subcategories represent the frequency of patients in each therapeutic regimen requiring oral steroids.
3Combo therapy refers to biologics plus aminosalicylates/6-mercaptopurine/methotrexate.
5-ASA: Aminosalicylates; AZA: Azathioprine; 6-MP: 6-Mercaptopurine; MTX: Methotrexate; IBD: Inflammatory bowel disease.